Do GLP-1 drugs actually reduce alcohol cravings while you're taking them?
Yes, the evidence is consistent across animal and early human studies that these drugs reduce alcohol intake and craving during active treatment. In a controlled lab setting, a 9-week trial of semaglutide in people with alcohol use disorder showed a significant reduction in both alcohol self-administration and craving [1]. Animal studies back this up: semaglutide dose-dependently reduced binge-like drinking in mice and rats, and also reduced drinking in rats that were dependent on alcohol [3]. Another study found that semaglutide, tirzepatide, and retatrutide all blunted the subjective 'feel' of alcohol in rats, which likely reduces its rewarding effects [2].
What happens to alcohol cravings after you stop taking a GLP-1 drug?
The evidence strongly suggests the benefits are not lasting after you stop the medication. The most direct data comes from a controlled animal study: after 15 days of semaglutide treatment, alcohol's effects returned to normal levels just three days after the last dose [2]. This means the drug was actively suppressing the alcohol response, and that suppression wore off quickly. A major 2026 review of the field confirms this gap, stating bluntly that there are 'no published data on whether drinking reductions or other clinical benefits are sustained without ongoing medication' [1]. The same review notes that when people stop GLP-1 drugs for weight loss, they typically regain much of the weight, suggesting these are chronic therapies that need to be continued to maintain effects [1].
So, are GLP-1 drugs a realistic long-term solution for alcohol use disorder?
They are promising, but not yet proven as a standalone long-term solution. The key issue is that alcohol use disorder is a chronic condition, and these drugs appear to work only as long as you take them [1][2]. This means they could be a powerful part of a treatment plan—like using them to help you achieve and maintain sobriety for a period while you build other skills and supports. However, there are currently no guidelines on how to safely stop them in the context of addiction, and no data on whether combining them with therapy (like cognitive behavioral therapy) would help sustain benefits after discontinuation [1]. The researchers are clear that rigorous clinical trials are still needed to answer these exact questions [1][4].
About These Sources
This answer is built on 4 peer-reviewed studies — published from 2023 to 2026, 2 from 2024 or later, 3 in Q1 journals, collectively cited 237 times — selected as the most relevant from 4 studies that passed quality screening, drawn from 42 papers retrieved from a database of over 500 million.
Sources used in this answer
Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
This 2026 review explicitly states there are no published data on whether drinking reductions or other clinical benefits from GLP-1 drugs are sustained after stopping the medication, and notes that discontinuation in metabolic patients typically leads to weight regain, suggesting these are chronic therapies.
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats
In a controlled animal study, semaglutide, tirzepatide, and retatrutide all reduced the subjective effects of alcohol in rats. Crucially, after 15 days of semaglutide treatment, alcohol discrimination returned to control levels just three days after treatment cessation, showing the effect is not lasting.
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
In rodent models, semaglutide dose-dependently reduced binge-like alcohol drinking in mice and rats, and also reduced drinking in alcohol-dependent rats, supporting its acute effects on alcohol intake during active treatment.
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
This 2023 perspective piece states that GLP-1 receptor agonists are promising but unproven treatments for alcohol use disorder, and emphasizes that existing approved treatments should be used until safety and efficacy are demonstrated in clinical trials.